Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARS PHARMACEUTICALS INC

13.15
+0.26002.02%
Post-market: 13.240.0900+0.68%19:49 EDT
Volume:1.79M
Turnover:23.27M
Market Cap:1.29B
PE:164.38
High:13.22
Open:12.80
Low:12.67
Close:12.89
Loading ...

BUZZ-ARS Pharma rises on expanded US approval for allergic reaction nasal spray

Reuters
·
06 Mar

Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY) and Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
06 Mar

ARS Pharmaceuticals Says US FDA Approves Lower Dosage of Neffy Nasal Spray

MT Newswires Live
·
06 Mar

BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions

Reuters
·
06 Mar

ARS Pharmaceuticals announces FDA approval for neffy 1 mg

TIPRANKS
·
06 Mar

US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients

Reuters
·
06 Mar

US FDA expands use of allergic reaction nasal spray in people between 15-30 kilograms

Reuters
·
06 Mar

ARS Pharmaceuticals Announces FDA Approval of Neffy® 1 Mg (Epinephrine Nasal Spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

THOMSON REUTERS
·
06 Mar

ARS Pharmaceuticals: Most Commercially Insured Patients Will Pay No More Than $25 for Two Single-Use Neffy Devices Through a Co-Pay Savings Program

THOMSON REUTERS
·
06 Mar

ARS Pharmaceuticals Inc - Neffy 1 Mg Is Expected to Be Available in U.S. by End of May 2025

THOMSON REUTERS
·
06 Mar

ARS Pharmaceuticals Inc: IF Product Isn't Covered by Insurance, Cash Price of $199 for Two Doses Is Available Through Blinkrx

THOMSON REUTERS
·
06 Mar

3 Growth Companies With High Insider Ownership Growing Earnings Up To 61%

Simply Wall St.
·
06 Mar

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

GlobeNewswire
·
04 Mar

ARS Pharmaceuticals (SPRY) Receives a Buy from William Blair

TIPRANKS
·
03 Mar

ARS Pharmaceuticals Inc : >:  Oppenheimer Initiates Coverage With Outperform Rating and Target Price $40

THOMSON REUTERS
·
10 Feb

Oppenheimer Initiates ARS Pharmaceuticals at Outperform

MT Newswires Live
·
10 Feb